Scarica l'app Stockscreener
3.27
0.91%
-0.03
Precedente Chiudi:
$3.30
Aprire:
$3.27
Volume 24 ore:
393.15K
Relative Volume:
0.68
Capitalizzazione di mercato:
$198.08M
Reddito:
-
Utile/perdita netta:
$-64.86M
Rapporto P/E:
-2.9196
EPS:
-1.12
Flusso di cassa netto:
$-55.66M
1 W Prestazione:
-1.21%
1M Prestazione:
+30.28%
6M Prestazione:
+147.73%
1 anno Prestazione:
+168.03%
Intervallo 1D:
$2.98
$3.35
Intervallo di 1 settimana:
$2.98
$3.495
Portata 52W:
$0.8551
$3.495
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Nome
Acumen Pharmaceuticals Inc
Settore
Industria
Telefono
617-344-4190
Indirizzo
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
3.27 | 198.08M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-07-26 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-20 | Ripresa | BofA Securities | Buy |
| 2023-05-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Iniziato | BTIG Research | Buy |
| 2022-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-07-26 | Iniziato | BofA Securities | Neutral |
| 2021-07-26 | Iniziato | Credit Suisse | Outperform |
| 2021-07-26 | Iniziato | Stifel | Buy |
| 2021-07-26 | Iniziato | UBS | Buy |
Mostra tutto
Acumen Pharmaceuticals Inc Borsa (ABOS) Ultime notizie
ABOS SEC FilingsAcumen Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Team members drive company mission, Acumen Pharmaceuticals, Inc. asserts - Traders Union
Acumen Pharma chief legal officer sells $6813 in stock By Investing.com - Investing.com Canada
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Bitget
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - GlobeNewswire Inc.
Stock Market Recap: What is the earnings history of Acumen Pharmaceuticals Inc2026 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Highs Report: Is Acumen Pharmaceuticals Inc a turnaround story2025 Fundamental Recap & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Spikes: What is the earnings history of Acumen Pharmaceuticals Inc2025 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acumen Pharmaceuticals to Highlight New Alzheimer’s Research Progress at AD/PD™ 2026 - citybiz
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.80 Consensus Price Target from Analysts - Defense World
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Acumen Pharma chief legal officer Meisner sells $28k in shares - Investing.com Australia
Acumen (NASDAQ: ABOS) CLO exercises options and sells 9,406 shares - Stock Titan
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 - mx.advfn.com
Acumen Pharmaceuticals to showcase advances in Alzheimer's treatment at international conference on Alzheimer's and Parkinson's diseases 2026 - marketscreener.com
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget
Acumen Pharmaceuticals To Showcase Advances In Alzheimer's Treatment At International Conference On Alzheimer’S And Parkinson’S Diseases 2026 - TradingView
New Alzheimer’s treatment data explores better delivery to the brain - Stock Titan
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Acumen Pharmaceuticals (ABOS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Acumen Pharmaceuticals (NASDAQ: ABOS) insider sells 9,406 shares - Stock Titan
ABOS Should I Buy - Intellectia AI
Profit Review: Can Acumen Pharmaceuticals Inc reach resistance levels soonTrend Reversal & Daily Chart Pattern Signals - baoquankhu1.vn
ABOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen - MarketBeat
Does Acumen Pharmaceuticals Inc. stock have upside surprise potentialJuly 2025 Spike Watch & Safe Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Market Trends: How is BlackSky Technology Inc Equity Warrant managing supply chain issuesJuly 2025 Recap & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Growth in Short Interest - Defense World
ABOS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will Acumen Pharmaceuticals Inc. stock reach Wall Street targetsWeekly Trend Report & Daily Risk Controlled Trade Plans - mfd.ru
Decliners Report: Is Acumen Pharmaceuticals Inc a cyclical or defensive stockJuly 2025 Summary & Long-Term Growth Plans - baoquankhu1.vn
ABOS PE Ratio & Valuation, Is ABOS Overvalued - Intellectia AI
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Increase in Short Interest - MarketBeat
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - The Malaysian Reserve
Can Acumen Pharmaceuticals Inc. stock sustain institutional interest2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - mfd.ru
Doseology Sciences Launches New Energy Product Line - Intellectia AI
Acumen Pharmaceuticals celebrates team contributions - Traders Union
Brokerages Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Price Target at $6.80 - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
While Institutions Invested in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Benefited From Last Week's 46% Gain, Private Equity Firms Stood to Gain the Most - 富途牛牛
Acumen Pharma CLO sells $53k in shares after option exercise - Investing.com Canada
Healthcare Stocks Surge in After-Hours Trading - intellectia.ai
Wall Street Analysts Adjust Ratings - intellectia.ai
Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments - Yahoo Finance
2026 Catalysts: Psychiatry, epilepsy and neurodegeneration - BioCentury
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $7.00 at BTIG Research - MarketBeat
Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative? - Sahm
Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Acumen Pharmaceuticals Inc Azioni (ABOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acumen Pharmaceuticals Inc Azioni (ABOS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Mar 06 '26 |
Sale |
3.26 |
2,090 |
6,813 |
173,999 |
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):